Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol,

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Dyslipidemia and Diabetic Macular Edema

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Wijtske Annema, PhD, Hendrik M

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Change in Lipid Profile in Celiac Disease: Beneficial Effect of Gluten-Free Diet Pardeep Brar, MD, Grace Y. Kwon, MD, Steve Holleran, BA, Diane Bai, MD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: A Meta-Analysis Sean P. Heffron, MD, MS, MSc, Amar Parikh, MD, Alexandar.

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study Tim Christen, MSc, Stella.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Eveline Oestreicher Stock, MD, Christine T

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

High frequency of type 2 diabetes and impaired glucose tolerance in Japanese subjects with the angiopoietin-like protein 8 R59W variant Jianhui Liu,

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Severe hypertriglyceridemia is primarily polygenic

In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction François Moreau, PhD, Claire Blanchard,

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Volume 67, Issue 4, Pages (April 2005)

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women Hong Zang, M.D., Kjell Carlström,

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity Christian Abendstein Kjellmo, MD, Helen Karlsson, PhD, Torunn K. Nestvold, MD, PhD, Stefan Ljunggren, PhD, Karin Cederbrant, PhD, Maritha Marcusson-Ståhl, BSc, Monica Mathisen, BLS, Knut Tore Lappegård, MD, PhD, Anders Hovland, MD, PhD Journal of Clinical Lipidology Volume 12, Issue 1, Pages 193-202 (January 2018) DOI: 10.1016/j.jacl.2017.10.007 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Serum levels of (A) LDL cholesterol, (B) HDL cholesterol, (C) triglycerides (TGs), and (D) apoB at inclusion, after a lifestyle intervention (∼3 months) and 1 year after bariatric surgery in 34 morbidly obese patients, and at inclusion for controls. Values are mean with standard deviation. *P < .05, **P < .01, ***P < .001, ****P < .0001, ns, not statistically significant. Journal of Clinical Lipidology 2018 12, 193-202DOI: (10.1016/j.jacl.2017.10.007) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Serum levels of the (A) large, boyant LDL (lbLDL) subfractions, (B) the small, dense LDL (sdLDL) subfractions, (C) large HDL subfractions, (D) small HDL subfractions at inclusion, after a lifestyle intervention (∼3 months) and 1 year after bariatric surgery in 34 morbidly obese patients, and at inclusion for controls. Values are mean with standard deviation. *P < .05, **P < .01, ***P < .001, ****P < .0001, ns, not statistically significant. Journal of Clinical Lipidology 2018 12, 193-202DOI: (10.1016/j.jacl.2017.10.007) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 3 A) Cholesterol efflux capacity (CEC), (B) Serum paraoxonase-1 (PON1) activity, and (C) serum amyloid A1/PON1 (SAA/PON1) ratio determined at inclusion, after a lifestyle intervention (∼3 months) and 1 year after bariatric surgery in 34 morbidly obese patients, and at inclusion for controls. Values are mean with standard deviation. *P < .05, **P < .01, ***P < .001, ****P < .0001, ns, not statistically significant. Journal of Clinical Lipidology 2018 12, 193-202DOI: (10.1016/j.jacl.2017.10.007) Copyright © 2017 National Lipid Association Terms and Conditions